3rd Quarter - Amendment

VIATRIS INC. for VIATRIS INC

Firm
Client
Income
—
Expenses
$440,000
Expense method
A: Lobbying Disclosure Act definitions

Versions of this report

Every filing the register holds for this firm, client and period, oldest first. The most recent one is the version LegiList counts.

Filing Filed Amount Counted
3rd Quarter - Report Oct 20, 2015 $390,000 Replaced
3rd Quarter - Amendment (this page) Apr 20, 2016 $440,000 Yes

What was lobbied

5 issue areas, each in the filer's own words, with who lobbied on it and where.

Budget/Appropriations BUD

Biosimilar Naming, Implementation of FDASIA and Generic Drug User Fee Act (GDUFA)

Foreign entity interest: As the parent entities of Mylan Inc., Mylan NV and Mylan Holdings Limited have a general interest in the issues above.

LobbyistCovered position, as disclosed
NIMISH SHAH —

Contacted: U.S. Trade Representative (USTR); HOUSE OF REPRESENTATIVES; White House Office; SENATE; Federal Trade Commission (FTC); Health & Human Services, Dept of (HHS)

Trade (domestic/foreign) TRD

Trans Pacific Partnership(TPP), General trade issues

Foreign entity interest: As the parent entities of Mylan Inc., Mylan NV and Mylan Holdings Limited have a general interest in the issues above.

LobbyistCovered position, as disclosed
NAWEL LILLIAN ROJKJAER —
NIMISH SHAH —

Contacted: HOUSE OF REPRESENTATIVES; U.S. Trade Representative (USTR); Federal Trade Commission (FTC); Health & Human Services, Dept of (HHS); White House Office; SENATE

Taxation/Internal Revenue Code TAX

Corporate Tax Reform, Proposals to reform domestic and international tax structures

Foreign entity interest: As the parent entities of Mylan Inc., Mylan NV and Mylan Holdings Limited have a general interest in the issues above.

LobbyistCovered position, as disclosed
NIMISH SHAH —

Contacted: U.S. Trade Representative (USTR); Health & Human Services, Dept of (HHS); Federal Trade Commission (FTC); White House Office; SENATE; HOUSE OF REPRESENTATIVES

Copyright/Patent/Trademark CPT

Patent Reform, H.R. 9 Innovation Act, S. 632 STRONG Patents Act, S. 2019 Preserve Access to Affordable Generics Act Access for Generics to Inter Partes Review (IPR)

Foreign entity interest: As the parent entities of Mylan Inc., Mylan NV and Mylan Holdings Limited have a general interest in the issues above.

LobbyistCovered position, as disclosed
NIMISH SHAH —

Contacted: SENATE; White House Office; HOUSE OF REPRESENTATIVES; Federal Trade Commission (FTC); Health & Human Services, Dept of (HHS); U.S. Trade Representative (USTR)

Bills named: S. 2019 (114th), H.R. 9 (114th), S. 632 (114th)

Health Issues HCR

Biosimilar Naming, Implementation of FDASIA and Generic Drug User Fee Act (GDUFA) Prescription drug pricing, Medicare Part D program and Generic Drugs HR 6 21st Century Cures Act; Innovation for Healthier Americans Initiative; Issues regarding market exclusivity Drug Supply Chain Security Act implementation of pharmaceutical distribution REMs program, H.R. 2841 FAST generics Act S. 1972 Airline Access to Emergency Epinephrine Act of 2015, Anaphylaxis awareness, access to epinephrine auto injector Issues related to the antitrust review of Teva Pharmaceuticals Industries, Ltd. offer to acquire Mylan N.V.

Foreign entity interest: As the parent entities of Mylan Inc., Mylan NV and Mylan Holdings Limited have a general interest in the issues above.

LobbyistCovered position, as disclosed
NIMISH SHAH —

Contacted: Health & Human Services, Dept of (HHS); U.S. Trade Representative (USTR); HOUSE OF REPRESENTATIVES; SENATE; Federal Trade Commission (FTC); White House Office

Bills named: H.R. 2841 (114th), H.R. 6 (114th), S. 1972 (114th)

Foreign entities

Foreign owners and affiliates the filer disclosed. Amounts are as declared on this filing.

EntityCountryPrincipal place of businessOwnershipContribution declared
MYLAN HOLDINGS LIMITED United Kingdom United Kingdom 100.0% —
MYLAN NV United Kingdom United Kingdom 100.0% —

Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.